AdAlta (ASX:1AD) has released new data on the potential efficacy of AD-214 in humans with Idiopathic Pulmonary Fibrosis and other fibrotic diseases. …
AdAlta releases new data on Phase 1 trial of AD-214 in Idiopathic Pulmonary Fibrosis
July 10, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News -
AUScelerate programs channel major investment into heart and diabetes innovations
July 30, 2026 - - Latest News -
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News